Treating COPD Patients with Inhaled Medications in the Era of COVID-19 and Beyond: Options and Rationales for Patients at Home.
Int J Chron Obstruct Pulmon Dis
; 16: 2687-2695, 2021.
Article
in English
| MEDLINE | ID: covidwho-1456164
ABSTRACT
COVID-19 has affected millions of patients, caregivers, and clinicians around the world. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads via droplets and close contact from person to person, and there has been an increased concern regarding aerosol drug delivery due to the potential aerosolizing of viral particles. To date, little focus has been given to aerosol drug delivery to patients with COVID-19 treated at home to minimize their hospital utilization. Since most hospitals were stressed with multiple admissions and experienced restricted healthcare resources in the era of COVID-19 pandemic, treating patients with COPD at home became essential to minimize their hospital utilization. However, guidance on how to deliver aerosolized medications safely and effectively to this patient population treated at home is still lacking. In this paper, we provide some strategies and rationales for device and interface selection, delivery technique, and infection control for patients with COPD who are being treated at home in the era of COVID-19 and beyond.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pharmaceutical Preparations
/
Pulmonary Disease, Chronic Obstructive
/
COVID-19
Type of study:
Diagnostic study
Limits:
Humans
Language:
English
Journal:
Int J Chron Obstruct Pulmon Dis
Year:
2021
Document Type:
Article
Affiliation country:
COPD.S332021
Similar
MEDLINE
...
LILACS
LIS